Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Melanoma 20Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Neoplasms 4Urinary Bladder Neoplasms 3Ovarian Neoplasms 3Carcinoma, Merkel Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Mesothelioma 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

HhAntag691 25Imiquimod 12Biopsy 12sonidegib 11Aminolevulinic Acid 9cemiplimab 8Photochemotherapy 8Nivolumab 8methyl 5-aminolevulinate 7Mohs Surgery 71-phenyl-3,3-dimethyltriazene 7Tomography, Optical Coherence 6Surgical Procedures, Operative 6Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Microscopy, Confocal 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Standard of Care 3Niacinamide 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × poly ICLC × Dermatologic × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡